| Recruiting | EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc) NCT07287670 | Mediar Therapeutics | Phase 2 |
| Recruiting | Controlling Hyperactive Immunity With Long-lived Lymphocytes NCT07473154 | Quell Therapeutics Limited | Phase 1 / Phase 2 |
| Not Yet Recruiting | Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis NCT04986605 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 |
| Recruiting | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease NCT06925542 | CRISPR Therapeutics | Phase 1 |
| Active Not Recruiting | A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases NCT06255028 | Century Therapeutics, Inc. | Phase 1 |
| Recruiting | Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis NCT06375005 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Not Yet Recruiting | US Zamto-cel Autoimmune Diseases NCT06708845 | Miltenyi Biomedicine GmbH | Phase 1 |
| Recruiting | A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis NCT06470048 | Novartis Pharmaceuticals | Phase 2 |
| Active Not Recruiting | CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 NCT06152172 | David Porter | Phase 1 |
| Recruiting | Open Label Extension Study of Brentuximab Vedotin in Early dcSSc NCT05149768 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 |
| Recruiting | Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative S NCT06936215 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 3 |
| Terminated | An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclero NCT05626751 | Amgen | Phase 2 |
| Active Not Recruiting | Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associa NCT05270668 | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Unknown | Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease. NCT05168215 | Elpen Pharmaceutical Co. Inc. | — |
| Withdrawn | A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis NCT05098145 | Talaris Therapeutics Inc. | Phase 1 / Phase 2 |
| Terminated | A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) NCT04478994 | Amgen | Phase 1 |
| Terminated | A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients NCT04781543 | Amgen | Phase 2 |
| Terminated | A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients NCT04837131 | Michael M. Pham | Phase 2 |
| Terminated | Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis NCT04680975 | Kadmon, a Sanofi Company | Phase 2 |
| Completed | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sc NCT04440592 | Tanabe Pharma America, Inc. | Phase 2 |
| Suspended | Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis NCT04166552 | Emerald Health Pharmaceuticals | Phase 2 |
| Withdrawn | Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) NCT04138485 | CSL Behring | Phase 2 |
| Completed | Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) NCT04137224 | CSL Behring | Phase 2 |
| Terminated | KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis NCT03919799 | Kadmon, a Sanofi Company | Phase 2 |
| Completed | Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis NCT03198689 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 |
| Terminated | Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis NCT03398837 | Corbus Pharmaceuticals Inc. | Phase 3 |
| Completed | Brentuximab Vedotin for Systemic Sclerosis NCT03222492 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis NCT02503644 | Inventiva Pharma | Phase 2 |
| Terminated | Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis NCT02465437 | Corbus Pharmaceuticals Inc. | Phase 2 |
| Completed | A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis NCT02161406 | Dinesh Khanna, MD, MS | Phase 2 |
| Completed | Mycophenolate Mofetil in Systemic Sclerosis NCT00433186 | Boston University | Phase 1 |